What were Gujarat Kidney & Super Speciality Ltd's latest quarterly results?
Gujarat Kidney & Super Speciality Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +46.2%
- Revenue Growth YoY: +97.2%
- Operating Margin: 29.7%
Gujarat Kidney & Super Speciality Ltd (Hospitals/Medical Services) — fundamental analysis, earnings data, and key metrics. PE: 81.8. ROE: 51.2%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Gujarat Kidney & Super Speciality Ltd's latest quarterly results (Dec 2025) show
Gujarat Kidney & Super Speciality Ltd's current PE ratio is 81.8x.
Gujarat Kidney & Super Speciality Ltd's price-to-book ratio is 24.0x.
Gujarat Kidney & Super Speciality Ltd's fundamental strength based on key financial ratios
Gujarat Kidney & Super Speciality Ltd has a debt-to-equity ratio of N/A.
Gujarat Kidney & Super Speciality Ltd's return ratios over recent years
Gujarat Kidney & Super Speciality Ltd's operating cash flow is positive (FY2025).
Gujarat Kidney & Super Speciality Ltd currently does not pay a significant dividend (yield 0.00%).
Gujarat Kidney & Super Speciality Ltd's shareholding pattern (Dec 2025)
Gujarat Kidney & Super Speciality Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Gujarat Kidney & Super Speciality Ltd may be worth studying
Gujarat Kidney & Super Speciality Ltd investment thesis summary:
Gujarat Kidney & Super Speciality Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.